(Q35088077)

6 August 2017

1 reference

title

The evolving role of direct thrombin inhibitors in acute coronary syndromes (English)

1 reference

6 August 2017

main subject

acute coronary syndrome

1 reference

1

John Eikelboom

1 reference

6 August 2017

3

Salim Yusuf

1 reference

6 August 2017

2

Harvey White

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

Journal of the American College of Cardiology

6 August 2017

published in

1 reference

6 August 2017

volume

41

1 reference

6 August 2017

issue

4 Suppl S

1 reference

6 August 2017

page(s)

70S-78S

1 reference

Are we mortgaging the medical profession?

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

The pathogenesis of coronary artery disease and the acute coronary syndromes (2).

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

Molecular and cellular biology of blood coagulation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

New antithrombotic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

Hirudins: from leeches to man.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

1 reference

7 January 2021

Highly selective tripeptide thrombin inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

Antithrombotic activity of inogatran, a new low-molecular-weight inhibitor of thrombin, in a closed-chest porcine model of coronary artery thrombosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

r-hirudin in unstable angina pectoris. Rationale and preliminary data from the APT pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

Recombinant hirudin and front-loaded alteplase in acute myocardial infarction: final results of a pilot study. HIT-I (hirudin for the improvement of thrombolysis)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

HBW 023 (recombinant hirudin) for the acceleration of thrombolysis and prevention of coronary reocclusion in acute myocardial infarction: results of a dose-finding study (HIT-II) by the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

Angiographic dose-finding study with r-hirudin (HBW 023) for the improvement of thrombolytic therapy with streptokinase (HIT-SK). Interim results

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

Usefulness and tolerability of hirulog, a direct thrombin-inhibitor, in unstable angina pectoris.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

Initial experience with a direct antithrombin, Hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

Clinical outcomes of bivalirudin for ischemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

A second look at bivalirudin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

Efficacy of hirudin in reducing cardiovascular events in patients with acute coronary syndrome undergoing early percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902687-6

7 January 2021

10.1016/S0735-1097(02)02687-6

Identifiers

DOI

1 reference

6 August 2017

1 reference